BioGend Therapeutics Statistics

Total Valuation

TPEX:6733 has a market cap or net worth of TWD 4.78 billion. The enterprise value is 4.27 billion.

Market Cap	4.78B
Enterprise Value	4.27B

Important Dates

The last earnings date was Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

TPEX:6733 has 124.36 million shares outstanding. The number of shares has decreased by -0.01% in one year.

Current Share Class	124.36M
Shares Outstanding	124.36M
Shares Change (YoY)	-0.01%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	4.18%
Owned by Institutions (%)	2.56%
Float	75.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	22.48
PB Ratio	6.13
P/TBV Ratio	7.22
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-41.61
EV / Sales	20.10
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-63.42

Financial Position

The company has a current ratio of 18.74, with a Debt / Equity ratio of 0.01.

Current Ratio	18.74
Quick Ratio	17.89
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.10
Interest Coverage	-657.79

Financial Efficiency

Return on equity (ROE) is -12.37% and return on invested capital (ROIC) is -7.86%.

Return on Equity (ROE)	-12.37%
Return on Assets (ROA)	-7.39%
Return on Invested Capital (ROIC)	-7.86%
Return on Capital Employed (ROCE)	-13.09%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	27
Asset Turnover	0.24
Inventory Turnover	3.25

Taxes

Income Tax	-8.31M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.08% in the last 52 weeks. The beta is 0.19, so TPEX:6733's price volatility has been lower than the market average.

Beta (5Y)	0.19
52-Week Price Change	+6.08%
50-Day Moving Average	40.92
200-Day Moving Average	34.56
Relative Strength Index (RSI)	41.82
Average Volume (20 Days)	206,537

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TPEX:6733 had revenue of TWD 212.43 million and -102.59 million in losses. Loss per share was -0.83.

Revenue	212.43M
Gross Profit	156.50M
Operating Income	-105.25M
Pretax Income	-110.77M
Net Income	-102.59M
EBITDA	-60.60M
EBIT	-105.25M
Loss Per Share	-0.83

Full Income Statement

Balance Sheet

The company has 531.20 million in cash and 6.65 million in debt, giving a net cash position of 524.55 million or 4.22 per share.

Cash & Cash Equivalents	531.20M
Total Debt	6.65M
Net Cash	524.55M
Net Cash Per Share	4.22
Equity (Book Value)	779.63M
Book Value Per Share	6.12
Working Capital	615.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -66.82 million and capital expenditures -493,000, giving a free cash flow of -67.31 million.

Operating Cash Flow	-66.82M
Capital Expenditures	-493,000
Free Cash Flow	-67.31M
FCF Per Share	-0.54

Full Cash Flow Statement

Margins

Gross margin is 73.67%, with operating and profit margins of -49.55% and -48.30%.

Gross Margin	73.67%
Operating Margin	-49.55%
Pretax Margin	-52.14%
Profit Margin	-48.30%
EBITDA Margin	-28.53%
EBIT Margin	-49.55%
FCF Margin	n/a

Dividends & Yields

TPEX:6733 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.01%
Shareholder Yield	0.01%
Earnings Yield	-2.15%
FCF Yield	-1.41%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TPEX:6733 has an Altman Z-Score of 42.57 and a Piotroski F-Score of 2.

Altman Z-Score	42.57
Piotroski F-Score	2